文献速递前列腺癌

MSH2缺陷前列腺癌的免疫反应与临床结局不同于结直肠癌或子宫内膜癌

MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-06-09

研究显示雄激素受体激活可破坏前列腺癌细胞MSH2基因,复发患者MSH2蛋白表达降低;TCGA队列中MSH2/6低表达前列腺癌患者结局显著更差,而子宫内膜癌和结直肠癌低表达患者则不然。错配修复缺陷的子宫内膜癌和结直肠癌呈现突变负荷增加、微卫星不稳定和免疫细胞动员增强,但前列腺癌中未见此现象。

要点

  • 雄激素受体激活可破坏前列腺癌MSH2基因,复发患者MSH2蛋白表达降低
  • TCGA队列中MSH2/6低表达前列腺癌患者结局显著更差
  • 前列腺癌MSH2/6丢失未伴随突变负荷、微卫星不稳定或免疫细胞动员的显著增加

核心结论

  • 前列腺癌中MSH2/MSH6蛋白丢失或降低与不良结局相关。
  • 该不良结局与突变负荷、微卫星不稳定或免疫细胞动员的统计学显著增加无关。

研究设计与样本

  • 筛选两个前列腺癌患者队列(复发/非复发)的肿瘤以确认MSH2蛋白表达缺失。
  • 对独立TCGA前列腺癌队列按MSH2/6表达分层分析结局。
  • 比较子宫内膜癌和结直肠癌中MSH2/6低表达与结局及免疫特征的关系。

主要发现

  • 复发前列腺癌病例中MSH2表达降低。
  • TCGA前列腺癌队列中MSH2/6低表达患者结局显著更差,而子宫内膜癌和结直肠癌低表达患者则相反。
  • 错配修复缺陷的子宫内膜癌和结直肠癌肿瘤显示突变负荷增加、微卫星不稳定和免疫细胞动员增强,但前列腺癌中不明显。

临床怎么用

  • 前列腺癌MSH2/MSH6表达降低提示预后不良,需加强随访监测。
  • 前列腺癌MSH2缺陷的免疫治疗策略不能简单套用结直肠癌或子宫内膜癌的错配修复缺陷范式。

局限性

  • 免疫特征分析基于原发性前列腺癌队列,未在转移性肿瘤中验证。
  • 未报告突变负荷、微卫星不稳定或免疫细胞动员的具体数值及统计学检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent publications have shown patients with defects in the DNA mismatch repair (MMR) pathway driven by either MSH2 or MSH6 loss experience a significant increase in the incidence of prostate cancer. Moreover, this increased incidence of prostate cancer is accompanied by rapid disease progression and poor clinical outcomes. METHODS AND RESULTS: We show that androgen-receptor activation, a key driver of prostate carcinogenesis, can disrupt the MSH2 gene in prostate cancer. We screened tumours from two cohorts (recurrent/non-recurrent) of prostate cancer patients to confirm the loss of MSH2 protein expression and identified decreased MSH2 expression in recurrent cases. Stratifying the independent TCGA prostate cancer cohort for MSH2/6 expression revealed that patients with lower levels of MSH2/6 had significant worse outcomes, in contrast, endometrial and colorectal cancer patients with lower MSH2/6 levels. MMRd endometrial and colorectal tumours showed the expected increase in mutational burden, microsatellite instability and enhanced immune cell mobilisation but this was not evident in prostate tumours. CONCLUSIONS: We have shown that loss or reduced levels of MSH2/MSH6 protein in prostate cancer is associated with poor outcome. However, our data indicate that this is not associated with a statistically significant increase in mutational burden, microsatellite instability or immune cell mobilisation in a cohort of primary prostate cancers.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. McCoy P, Mangiola S, Macintyre G, et al. MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 34108644. doi:10.1038/s41391-021-00379-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。